Novartis to acquire Avidity Biosciences for about $12B

Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.

  Business   Oct 27, 2025   0   5  Add to Reading List
Novartis to acquire Avidity Biosciences for about $12B
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow